Skip to main content
Premium Trial:

Request an Annual Quote

Gene Logic Spurs Management Changes; Bruker Fleshes Out Board; NHGRI Hires New Cancer Head; GE s Carr Moves On; and Others

Bruker Biosciences has appointed Jörg Laukien to its board of directors as a Class III director. He starts Jan. 1, 2005.  He is a director and president of Bruker BioSpin MRI, Inc.; president of Bruker BioSpin MRI GmbH; president of Bruker Elektronic GmbH; director of Bruker BioSpin Inc.; director of Bruker BioSpin SA;  director of Bruker BioSpin s.r.l.; and director of Techneon.

 

Laukien owns 14.3 percent of Bruker stock. The company's five largest stockholders are Frank Laukien, Dirk Laukien, Isolde Laukien, Jörg Laukien, and Marc Laukien. Isolde Laukien is the mother of Dirk and Marc Laukien. Jörg, Frank, Dirk, and Marc are brothers or half-brothers.


 

Gene Logic announced several management changes in its recent conference call to discuss its quarterly financial results. The firm has hired Dennis Rossi, most recently vice president of life science marketing at Accelrys, for the newly created position of senior vice president and general manager of genomics and information services. Gene Logic also hired Carlos Orantes, a former Covance executive, as vice president of operations for Gene Logic Laboratories, which is the preclinical toxicology research business that the company created after acquiring InterMune last year.

 

Gene Logic CEO Mark Gessler said that the new hires were made "to restructure our business model under new leadership and to improve our performance significantly." They follow a six-month assessment of "key issues" that have led to the company's lackluster performance, Gessler said.

 

Rossi and Orantes will be responsible for all aspects of the two business units, and will report directly to Gessler, according to BioInform,a GenomeWeb News publication. "This leaves Gessler to take a more global view of the company, its ongoing strategy and, ultimately, more time to affect things that can take the company in the direction he wants it to go."

 

Gene Logic has also elected J. Stark Thompson to be non-executive chairman of the board. Thompson, 63, has be a Gene Logic director since February 2002.

 

Thompson's election is the result of Gene Logic's decision to separate the roles of chairman and CEO. The company said it believes the decision "will further enhance Gene Logic's corporate governance standards and practices and will enable the company to better capitalize on its senior management resources," it said in a statement.

 

Thompson was formerly president and CEO of Life Technologies, a developer, manufacturer and supplier of products and services for life science research and biotechnology production, from 1988 until his retirement in 2000.


 

The National Human Genome Research Institute has named Elaine Ostrander as chief of its Cancer Genetics Branch, one of the seven research branches in the Division of Intramural Research.

 

Ostrander comes to the NHGRI from the FredHutchinsonCancerResearchCenter, in Seattle. She received a BS in 1981 from the Universityof Washington, and a PhD in 1987 from OregonHealth & SciencesUniversityin Portland.


 

Bionomics has appointed Peter Jonson as chairman. The board also extended the contract term of Deborah Rathjen, CEO and managing director, until June 2008.

 

Jonson will succeed Fraser Ainsworth, who announced in July that he intended to retire as a director. Jonson previously chaired the Australian federal government's Biotechnology Centre of Excellence Expert Panel and the Major National Research Facilities Committee.


 

VisiGen Biotechnologies has appointed as a director Richard Gibbs, founder of SeqWright and director of the Baylor College of Medicine HGSC. The appointment is tied to a partnership VisiGen and SeqWright announced on Nov. 9 to co-develop VisiGen's DNA sequencing technology.


 

InforSense has appointed to its scientific advisory board Michael Liebman, of  the Windber Research Institute; Tim Clark, of the Universität Erlangen-N rnberg, in Germany; and Peter Donnelly, of Oxford University.

 

Liebman has been chief scientific officer at Windber Research Institute since November 2003. He has also been director of computational biology and biomedical informatics at the Abramson Family Cancer Research Institute of the University of Pennsylvania Cancer Center.

 

Clarkis currently the technical director of the Computer-Chemie-Centrum at the Universität Erlangen-N rnberg. He obtained his PhD from the Queen's University Belfast.

 

Donnelly is a professor of statistical science at the Universityof Oxfordand was head of the Department of Statistics from 1996 - 2001. He currently heads the Oxford University Bioinformatics and Mathematical Genetics groups


 

Predicant Biosciences has appointed Richard Bastiani to its board of directors. Bastiani is currently chairman of ID Biomedical, a human vaccine company. He also serves on the board of Abaxis, which specializes in point-of-care diagnostics, and is a director and co-founder of DiscoverRx, which is focused on high-throughput screening and proteomics products for pharmaceutical drug discovery.


 

PointOne Systems has appointed PointOneco-founder Peter Tonellato as vice president of business development and chief scientific officer. Tonellato will leave his primary faculty appointment at the Medical College of Wisconsin, but will continue to "interact" with the Department of Physiology and the Human and MolecularGeneticsCenterin areas of "mutual research interest."

 

Tonellato also founded and was director of the BioinformaticsResearchCenter, part of the HMGC, at the Medical College of Wisconsin.  He was also founding director of the joint MCW, MarquetteUniversitygraduate program in bioinformatics.


 

Chiron has created the position of chief operating officer on an interim basis, and has hired Jack Goldstein, previously president of Chiron Blood Testing, to fill it. The company also appointed of Anne Hill as vice president of human resources, and Meghan Leader vice president of business support and chief information officer.

 

Gene Walther, currently vice president for Chiron Blood Testing commercial operations in the Americaswill become acting president of Chiron Blood Testing.

 

Goldstein joined Chiron in September 2002 as president of Chiron Blood Testing. He worked at Johnson & Johnson for 11 years in a "variety" of executive positions, including president of Ortho Diagnostic Systems and executive vice president of professional diagnostics of Johnson & Johnson.

 

Hill joins Chiron from Baxter International, where she served in a "variety" of executive positions from 1991 to 2004. From 1997 to 2004, she was vice president of human resources for Baxter Bioscience.

 

Prior to joining Chiron in 1998, Walther held executive management positions in sales, marketing, and business development at Gen-Probe, Abbott Diagnostics, and American Hospital Supply Corporation.

 

Leader joined Chiron more than 12 years ago, serving most recently as vice president and CIO.


 

Mark Pykett will join Boston Life Sciences as executive vice president and chief operating officer, the company said last week. Pykett joins the company from Cytomatrix, where he was president and CEO. Cytomatrix recently merged with CyGenics.

 

Additionally, Robert Gipson and Marc Lanser resigned from Boston Life Science's board of directors. Lanser will remain as president and chief science officer of BLS.


 

Andrew Carr, former president of discovery systems for GE Healthcare, is now functioning in an advisory role within the company. Carr was replaced by Joel McComb in August, who joined the company from a position as president and CEO of Innovadyne Technologies. McComb's previous work experience included a position heading the primary care division of Beckman Coulter.


 

Bill Linton, chairman and CEO of Promega, has been elected chairman of the Analytical and Life Science Systems Association, the molecular-biology tools industry trade group said last month. Linton succeeds Joe Keegan of Molecular Devices.

 

Peter Coggins, president of PerkinElmer's Life and Analytical Sciences unit, was elected vice chairman and chairman-elect of the group.

 

Lukas Braunschweiler, president and CEO of Dionex; Benjamin Bulkley, senior vice president for commercial operations of Invitrogen; Joel McComb, president, Discovery Systems, GE Healthcare; Brian McKernan, CEO of Agencourt Bioscience; and Volker Pfahlert, head of Roche Applied Science, were elected to the organization's board of directors.

 

According to the organization, nine directors were reelected, including: Arthur Caputo, president, Waters Division of Waters Corp.; Marc Casper, president, Life & Laboratory Sciences, Thermo Electron; Haseeb Chaudhry, CEO of Alpha Innotech; Jay Flatley, president and CEO of llumina; Lissa Goldenstein, president and CEO of Argonaut Technologies; Laura Lauman, president, proteomics and small molecule division of Applied Biosystems; Riccardo Pigliucci, chairman and CEO, Discovery Partners International; Garry Rogerson, president and CEO, Varia.; and Chris van Ingen, president, Life Science & Chemical Analysis, of Agilent Technologies, the group said.


 

Spectrum Pharmaceuticals has appointed Kolli Prasad as director of the company's research and development department. Prasad comes to the position from Shantha Biotechnics, where he served for ten years as head of R&D.


 

Diversa has appointed Fernand Kaufmann as a director. Kaufmann served on the senior management team and management executive committee of The Dow Chemical Company before retiring in 2001.

 

Kaufmann currently serves as chairman of HPL SA, a Swiss technology start-up company in the field of novel lithium-ion battery technology and as an advisor to two private equity funds. He received a PhD in Polymer Chemistry from the Universityof Strasbourgin France.


 

Orchid BioSciences has hired Nicholas Conti to the newly created position of vice president of corporate development. Conti most recently served as vice president of research and development and business operations of a new unit at Becton Dickinson. At Orchid, Conti's "initial" responsibilities will be to prioritize new markets for DNA testing services and applying a variety of approaches to strengthen Orchid's presence in existing segments.

 

Conti has a BS from Notre Dame, a PhD in chemistry from the Universityof Florida, and an MBA from the WhartonSchoolat the Universityof Pennsylvania.


 

Lion Biosciences has appointed form CEO Friedrich von Bohlen, Christoph Mutter, and Jan Traenckner as new members of its supervisory board. Von Bohlen, who left the company last December, has been elected chairman, while Traenckner has been elected deputy chairman, and Mutter was named chairman of the audit committee.

 

The three men replace Juergen Dormann, Klaus Pohle, and Richard Roy, who resigned their seats on the supervisory board on Oct. 13.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.